Abstract: A semiconductor device according to the present technology includes a semiconductor chip, and a wiring board portion having the semiconductor chip mounted thereon and having an external connection terminal for establishing electrical connection to the outside, the external connection terminal being formed on its back surface which is a surface opposite to its front surface which is a surface on which the semiconductor chip is mounted, in which the semiconductor chip is connected to a terminal formed on the front surface of the wiring board portion through a bonding wire to be wire-bonded to the wiring board portion, and a heat dissipation member is disposed between the bonding wire and the wiring board portion.

Abstract: A support stage includes a base portion, a support portion that is erected at a peripheral edge portion of the base portion and with which one surface of a wafer is to be come into contact, a suction groove that is provided at the support portion and to which a suction force with respect to the one surface is to be given, an ejecting hole that is provided in an inward portion of the base portion and by which a gas is to be ejected toward the one surface, and an exhaust hole that is provided in at least either one of the base portion and the support portion and by which a gas is to be discharged from a space between the base portion, the support portion, and the one surface.

Abstract: To prevent unnecessary light ray reflection in a semiconductor module employing a chip-on-chip structure or a chip-on-wafer structure. The semiconductor module includes a substrate, first and second semiconductor elements, and a cover part. The first semiconductor element is arranged on the substrate. The first semiconductor element includes a wiring electrically connected to the substrate and a pixel region of an imaging element on an upper surface opposite to a surface facing the substrate. The second semiconductor element is arranged at a position different from the pixel region on the upper surface of the first semiconductor element. The cover part covers the first and second semiconductor elements from the upper surface with respect to at least a part of a region excluding the pixel region.

Abstract: Circuits are added while an increase in size of a semiconductor package is prevented. The semiconductor package includes a transparent member; an embedding resin; an embedded circuit; and a solid-state image pickup element. In the semiconductor package, the embedding resin is formed around the transparent member. Further, in the semiconductor package, the embedded circuit is embedded in the embedding resin. Further, in the semiconductor package, the solid-state image pickup element performs photoelectric conversion on light that has passed through the transparent member and thereby generates image data.

Abstract: In a wired substrate, heat dissipation performance is improved while an increase in an amount of metal is inhibited. The substrate includes a transmission line, an insulating material, and a heat storage material. In the substrate provided with the transmission line, the insulating material and the heat storage material, the transmission line transmits a predetermined electrical signal from a semiconductor chip. The transmission line for transmitting the predetermined electrical signal from the semiconductor chip is wired in the insulating material. The heat storage material has a higher thermal conductivity than the insulating material to which the transmission line is wired and accumulates latent heat accompanying phase transition that occurs within an operating temperature range of the semiconductor chip.

Abstract: A method for inducing the differentiation of stem cells into tissue cells; a bioartificial organ, which contains the tissue cells; and a material for medical purposes, which contains the bioartificial organ are disclosed. Stem cells capable of proliferation, self-replication and differentiation are used and cultured by a hanging-drop method to three-dimensionally construct a cell mass of embryoid bodies, and the cell mass is cultured in the presence of HGF, GDNF, b-FGF, BMP7 and EGF. In this manner, the stem cells can be differentiated into tissue cells. A bioartificial organ can be produced using cells that have been differentiated into the tissue cells. Further, a material for medical purposes can be provided.

Abstract: A therapeutic agent containing Vasohibin for diabetic nephropathy, and a therapeutic agent containing Vasohibin for peritoneal sclerosis. Since the therapeutic agent containing Vasohibin of the present invention is a substance in which Vasohibin inhibits angiogenesis in an autocrine manner, the therapeutic agent is effective for inhibiting the progression of diabetic nephropathy and peritoneal sclerosis in which the inhibition in the angiogenesis or the production of cytokine is important, so that the therapeutic agent is suitably used in, for example, the treatment of a disease requiring an action for inhibiting the progression of diabetic nephropathy, and a disease requiring an inhibitory action for peritoneal sclerosis, or the like.

Abstract: It is intended to provide a method of detecting the onset of pregnancy toxemia whereby the onset risk of pregnancy toxemia can be adequately evaluated. Namely, a method of detecting the onset of pregnancy toxemia in a pregnant mammal which comprises the measurement step of measuring the concentration of angiopoietin-2 in a body fluid, the comparison step of comparing the angiopoietin-2 concentration obtained in the above measurement step with a normal level, and the judgment step of judging the presence or absence of the onset risk of pregnancy toxemia based on the results of the above comparison step. In the judgment step, it may be considered that the patient has a risk of the onset of pregnancy toxemia in the case where the angiopoietin-2 concentration obtained in the measurement step is lower than the normal level.

Abstract: A therapeutic agent containing Vasohibin for diabetic nephropathy, and a therapeutic agent containing Vasohibin for peritoneal sclerosis. Since the therapeutic agent containing Vasohibin of the present invention is a substance in which Vasohibin inhibits angiogenesis in an autocrine manner, the therapeutic agent is effective for inhibiting the progression of diabetic nephropathy and peritoneal sclerosis in which the inhibition in the angiogenesis or the production of cytokine is important, so that the therapeutic agent is suitably used in, for example, the treatment of a disease requiring an action for inhibiting the progression of diabetic nephropathy, and a disease requiring an inhibitory action for peritoneal sclerosis, or the like.

Abstract: It is intended to provide a method of detecting the onset of pregnancy toxemia whereby the onset risk of pregnancy toxemia can be adequately evaluated. Namely, a method of detecting the onset of pregnancy toxemia in a pregnant mammal which comprises the measurement step of measuring the concentration of angiopoietin-2 in a body fluid, the comparison step of comparing the angiopoietin-2 concentration obtained in the above measurement step with a normal level, and the judgment step of judging the presence or absence of the onset risk of pregnancy toxemia based on the results of the above comparison step. In the judgment step, it may be considered that the patient has a risk of the onset of pregnancy toxemia in the case where the angiopoietin-2 concentration obtained in the measurement step is lower than the normal level.

Abstract: A pharmaceutical composition for treating and preventing diseases, disorders and/or conditions of airway inflammation, airway stenosis or nasal cavity inflammation caused by the expression of a gene regulated by NF-kappaB which contains an NF-kappaB decoy and a pharmaceutically acceptable carrier. The above diseases may be asthma, COPD or rhinitis. Moreover, the above diseases may be diseases caused by an eosinophil abnormality (for example, asthma, rhinitis and COPD). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome and so on.

Abstract: A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-?B or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-?B decoy, an ets decoy, or a chimera decoy of NF-?B and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

Abstract: A pharmaceutical composition is provided for treatment and/or prevention of a disease, a disorder and/or a condition caused by expression of a gene controlled by NF-&kgr;B or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-&kgr;B decoy, an ets decoy, or a chimera decoy of NF-&kgr;B and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. Alternatively, the disease is a disease associated with eosinophilic abnormality (e.g., asthma, vascular diseases, allergic diseases, parasite diseases). The pharmaceutically acceptable carrier may be a hydrophilic polymer, a liposome, or the like.

Abstract: The specification relates to a preparation for the prophylaxis or treatment of renal diseases, and a method for the prophylaxis or treatment of renal diseases, and specifically, it relates to the above preparation and method using a sulfated polysaccharide as an active ingredient.